NeutroD
Research type
Research Study
Full title
Evaluation of the diagnostic performance of Neutrocheck® compared with standard-of-care neutrophil and CRP readings in patients at risk of neutropenic sepsis
IRAS ID
331579
Contact name
Hugo Ford
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Trust
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
The aim of the NeutroD study is to assess the accuracy of a device - Neutrocheck – within a hospital setting, on patients with neutropenia. Neutropenia is a common side effect of chemotherapy and is characterised by low levels of neutrophils, which are a type of white blood cell. This increases the likelihood of a patient further developing neutropenic sepsis, a life-threatening condition that causes approximately 800 deaths/year in England and Wales.
Neutropenic sepsis is diagnosed via blood test which measures the levels of both neutrophils and a protein called C-reactive protein (CRP). If the blood test shows low levels of neutrophils and high CRP, then a patient is at risk of getting neutropenic sepsis. The standard of care for such patients is to receive antibiotics intravenously. This means the antibiotics, medication used to fight off the infection, are administered directly into a vein in the arm whilst the patient awaits results (15min-2hrs) from the blood test.
The Neutrocheck device will detect neutrophil and CRP levels using just a finger prick of blood. The patient will then review their results using a colour chart and app. If Neutrocheck is as accurate as hospital laboratory tests, this could lead to the possibility of patients doing the tests at home so they would come into the hospital only if it was necessary, and receive results much faster than current hospital result waiting times. This further ensures antibiotic treatment is only administered to patients who require it.
The NeutroD study is looking to recruit patients who are at risk of neutropenia or neutropenic sepsis at Addenbrooke’s Hospital, Cambridge. Participants will test the Neutrocheck device, and participation is expected to last less than an hour.REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
24/EE/0195
Date of REC Opinion
5 Nov 2024
REC opinion
Further Information Favourable Opinion